Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis Expands Rimonabant Diabetes Program With Multiple Trials

Executive Summary

Sanofi-Aventis is expanding its Zimulti (rimonabant) diabetes program after clinical study results showed the drug's effectiveness in reducing HbA1c is comparable to oral anti-diabetics

You may also be interested in...



Sanofi Outlines Plans To Establish Lantus As Leading Worldwide Anti-Diabetic

Sanofi-Aventis aims to establish its long-acting insulin Lantus (insulin glargine injection) as the leading anti-diabetic worldwide by marketing it for combination use as well as a stand-alone product

Sanofi Outlines Plans To Establish Lantus As Leading Worldwide Anti-Diabetic

Sanofi-Aventis aims to establish its long-acting insulin Lantus (insulin glargine injection) as the leading anti-diabetic worldwide by marketing it for combination use as well as a stand-alone product

FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count

Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved

Related Content

UsernamePublicRestriction

Register

PS048828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel